Publication - Progress report
New Medicines Reviews 2013
Reports on the role of SMC & Review of IPTR & ADTC
Appendix 4: NHS board decisions for each medicine
The table below illustrates the count of boards for each decision category, for each medicine.
| ADTC Decision Categories* | % of boards that | |||||||
|---|---|---|---|---|---|---|---|---|
| Medicine | 1 | 2 | 3 | 4 | 5 | 6 | Included this drug on formularies |
Excluded this drug on formularies |
| Insulin detemir (Levemir) | 12 | 0 | 0 | 0 | 0 | 0 | 100% | 0% |
| Mercaptopurine (Xaluprine) | 12 | 0 | 0 | 0 | 0 | 0 | 100% | 0% |
| Tocilizumab (RoActemra) | 11 | 1 | 0 | 0 | 0 | 0 | 100% | 0% |
| Etanercept (Enbrel) (782/12) | 11 | 0 | 1 | 0 | 0 | 0 | 92% | 8% |
| Pregablin oral solution (Lyrica) | 11 | 0 | 0 | 0 | 1 | 0 | 92% | 8% |
| Exenatide (Byetta) | 11 | 0 | 0 | 0 | 1 | 0 | 92% | 8% |
| Abiraterone (Zytiga) | 11 | 0 | 0 | 0 | 0 | 1 | 92% | 8% |
| Colecalciferol (Fultium-D3) | 10 | 1 | 0 | 0 | 0 | 1 | 92% | 8% |
| Everolimus (Afinitor) | 10 | 0 | 1 | 0 | 0 | 1 | 83% | 17% |
| Etanercept (Enbrel) (781/12) | 10 | 0 | 1 | 0 | 1 | 0 | 83% | 17% |
| Alteplase (Actilyse) | 10 | 0 | 1 | 0 | 1 | 0 | 83% | 17% |
| Eplerenone (Inspra) | 9 | 1 | 0 | 0 | 1 | 1 | 83% | 17% |
| Fidaxomicin (Dificlir) | 8 | 2 | 0 | 0 | 0 | 2 | 75% | 25% |
| Tadalafil (Adcirca) | 8 | 1 | 0 | 3 | 0 | 0 | 75% | 25% |
| Rufinamide (Inovelon®) | 8 | 1 | 0 | 2 | 1 | 0 | 75% | 25% |
| Fingolimod (Gilenya) | 9 | 0 | 0 | 0 | 1 | 2 | 75% | 25% |
| Tobramycin (TOBI Podhaler) | 8 | 0 | 0 | 2 | 1 | 1 | 67% | 33% |
| Dexamethasone (Ozurdex) | 7 | 1 | 0 | 0 | 2 | 2 | 67% | 33% |
| Pegylated interferon alfa 2b (Viraferon Peg) | 6 | 1 | 0 | 2 | 2 | 1 | 58% | 42% |
| Dexmedetomidine hydrochloride (Dexdor) | 6 | 0 | 0 | 2 | 1 | 3 | 50% | 50% |
| Collagenase (Xiapex) | 5 | 0 | 0 | 3 | 2 | 2 | 42% | 58% |
| Golimumab (simponi) | 5 | 0 | 0 | 6 | 0 | 1 | 42% | 58% |
| Tegafur/gimeracil/oteracil (Teysuno) | 2 | 0 | 0 | 7 | 1 | 2 | 17% | 83% |
* ADTC decision categories:
- Included on the NHS board formulary (to include specialist, approved, additional lists) for the indication in question;
- Included pending protocol;
- Not included* from the NHS board formulary because the NHS board decision is that the medicine does not represent sufficient added benefit to other comparator medicines to treat the condition in question which are already available in the formulary;
- Not included* from the NHS board formulary because clinicians do not support the formulary inclusion;
- Not included* from the NHS board formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine;
- Not included* pending protocol.
Contact
Email: VERONICA MOFFAT
There is a problem
Thanks for your feedback